Improved immunological tolerance following combination therapy with CTLA-4/ig and AAV-mediated PD-l1/2 muscle gene transfer

Frontiers in Microbiology

Volumn 2, Issue SEP, 2011, Pages

  Adriouch, Sahil ^a,b   Franck, Emilie ^a,b   Drouot, Laurent ^a,b   Bonneau, Carole ^a   Jolinon, Nelly ^c   Salvetti, Anna ^c   Boyer, Olivier ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c UNIVERSITÉ DE LYON   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

AAV vectors; Costimulation; CTLA 4; Gene therapy; PD 1; PD L1; PD L2; Tolerance

Indexed keywords

EID: 84860509195     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2011.00199     Document Type: Article

References (53)

1. Bluestone, J. A., St Clair, E. W., and Turka, L. A. (2006). CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24, 233-238.
2. Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., and Thompson, C. B. (1995). CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity 3, 87-98.
3. Brockstedt, D. G., Podsakoff, G. M., Fong, L., Kurtzman, G., Mueller-Ruchholtz, W., and Engleman, E. G. (1999). Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. 92, 67-75.
4. Calbo, S., Delagreverie, H., Arnoult, C., Authier, F. J., Tron, F., and Boyer, O. (2008). Functional tolerance of CD8+ T cells induced by musclespecific antigen expression. J. Immunol. 181, 408-417.
5. Carter, L., Fouser, L. A., Jussif, J., Fitz, L., Deng, B., Wood, C. R., Collins, M., Honjo, T., Freeman, G. J., and Carreno, B. M. (2002). PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur. J. Immunol. 32, 634-643.
6. Du, L., Zhao, G., Lin, Y., Sui, H., Chan, C., Ma, S., He, Y., Jiang, S., Wu, C., Yuen, K. Y., Jin, D. Y., Zhou, Y., and Zheng, B. J. (2008). Intranasal vaccination of recombinant adeno-associated virus encoding receptorbinding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides longterm protection against SARS-CoV infection. J. Immunol. 180, 948-956.
7. Dumont, F. J. (2004). Technology evaluation: abatacept, Bristol-Myers Squibb. Curr. Opin. Mol. Ther. 6, 318-330.
8. Fife, B. T., and Bluestone, J. A. (2008). Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224, 166-182.
9. Fisher, K. J., Jooss, K., Alston, J., Yang, Y., Haecker, S. E., High, K., Pathak, R., Raper, S. E., and Wilson, J. M. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3, 306-312.
10. Francisco, L. M., Sage, P. T., and Sharpe, A. H. (2010). The PD-1 pathway in tolerance and autoimmunity. Immunol. Rev. 236, 219-242.
11. Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., Horton, H. F., Fouser, L., Carter, L., Ling, V., Bowman, M. R., Carreno, B. M., Collins, M., Wood, C. R., and Honjo, T. (2000). Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027-1034.
12. Gao, G., Wang, Q., Calcedo, R., Mays, L., Bell, P., Wang, L., Vandenberghe, L. H., Grant, R., Sanmiguel, J., Furth, E. E., and Wilson, J. M. (2009). adeno-associated virusmediated gene transfer to nonhuman primate liver can elicit destructive transgenespecific T cell responses. Hum. Gene Ther. 20, 930-942.
13. Grabie, N., Gotsman, I., DaCosta, R., Pang, H., Stavrakis, G., Butte, M. J., Keir, M. E., Freeman, G. J., Sharpe, A. H., and Lichtman, A. H. (2007). Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart. Circulation 116, 2062-2071.
14. Green, J. M., Noel, P. J., Sperling, A. I., Walunas, T. L.,Gray, G. S., Bluestone, J. A., and Thompson, C. B. (1994). Absence of B7-dependent responses in CD28-deficient mice. Immunity 1, 501-508.
15. Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., and Puccetti, P. (2002). CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3, 1097-1101.
16. Halbert, C. L., Standaert, T. A., Wilson, C. B., and Miller, A. D. (1998). Successful readministration of adeno-associated virus vectors to the mouse lung requires transient immunosuppression during the initial exposure. J. Virol. 72, 9795-9805.
17. Ishida, M., Iwai, Y., Tanaka, Y., Okazaki, T., Freeman, G. J., Minato, N., and Honjo, T. (2002). Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues. Immunol. Lett. 84, 57-62.
18. Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., and Minato, N. (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99, 12293-12297.
19. June, C. H., Ledbetter, J. A., Linsley, P. S., and Thompson, C. B. (1990). Role of the CD28 receptor in T-cell activation. Immunol. Today 11, 211-216.
20. Kessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., and Byrne, B. J. (1996). Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc. Natl. Acad. Sci. U.S.A. 93, 14082-14087.
21. Klein, C. J., Coovert, D. D., Bulman, D. E., Ray, P. N., Mendell, J. R., and Burghes, A. H. (1992). Somatic reversion/suppression in duchenne muscular dystrophy (DMD): evidence supporting a framerestoring mechanism in rare dystrophinpositive fibers. Am. J. Hum. Genet. 50, 950-959.
22. Kuck, D., Lau, T., Leuchs, B., Kern, A., Muller, M., Gissmann, L., and Kleinschmidt, J. A. (2006). Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J. Virol. 80, 2621-2630.
23. Larsen, C. P., Pearson, T. C., Adams, A. B., Tso, P., Shirasugi, N., Strobert, E., Anderson, D., Cowan, S., Price, K., Naemura, J., Emswiler, J., Greene, J., Turk, L. A., Bajorath, J., Townsend, R., Hagerty, D., Linsley, P. S., and Peach, R. J. (2005). Rational development of LEA29Y (belatacept), a highaffinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5, 443-453.
24. Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., Greenfield, E. A., Bourque,K.,Boussiotis,V. A.,Carter, L. L., Carreno, B. M., Malenkovich, N., Nishimura, H., Okazaki, T., Honjo, T., Sharpe, A. H., and Freeman, G. J. (2001). PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2, 261-268.
25. Lenschow, D. J., Zeng,Y., Thistlethwaite, J. R., Montag, A., Brady, W., Gibson, M. G., Linsley, P. S., and Bluestone, J. A. (1992). Longterm survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257, 789-792.
26. Lin, J., Zhi, Y., Mays, L., and Wilson, J. M. (2007a). Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. J. Virol. 81, 11840-11849.
27. Lin, S. W., Hensley, S. E., Tatsis, N., Lasaro, M. O., and Ertl, H. C. (2007b). Recombinant adeno-associated virus vectors induce functionally impaired transgene productspecific CD8+ Tcells in mice. J. Clin. Invest. 117, 3958-3970.
28. Lorain, S., Gross, D. A., Goyenvalle, A., Danos, O., Davoust, J., and Garcia, L. (2008). Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles. Mol. Ther. 16, 541-547.
29. Lu, Y., and Song, S. (2009). Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc. Natl. Acad. Sci. U.S.A. 106, 17158-17162.
30. Manning, W. C., Paliard, X., Zhou, S., Pat Bland, M., Lee, A. Y., Hong, K., Walker, C. M., Escobedo, J. A., and Dwarki, V. (1997). Genetic immunization with adeno-associated virus vectors expressing herpes simplex virustype2glycoproteinsBandD. J. Virol. 71, 7960-7962.
31. Manning, W. C., Zhou, S., Bland, M. P., Escobedo, J. A., and Dwarki, V. (1998). Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9, 477-485.
32. Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., Dake, M., Kaye, R., Razavi, M., Zajko, A., Zehnder, J., Rustagi, P. K., Nakai, H., Chew, A., Leonard, D., Wright, J. F., Lessard, R. R., Sommer, J. M., Tigges, M., Sabatino, D., Luk, A., Jiang, H., Mingozzi, F., Couto, L., Ertl, H. C., High, K. A., and Kay, M. A. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat. Med. 12, 342-347.
33. Mays, L. E., and Wilson, J. M. (2011). The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol. Ther. 19, 16-27.
34. McCaffrey, A. P., Fawcett, P., Nakai, H., McCaffrey, R. L., Ehrhardt, A., Pham, T. T., Pandey, K., Xu, H., Feuss, S., Storm, T. A., and Kay, M. A. (2008). The host response to adenovirus, helper-dependent adenovirus, and adeno-associated virus in mouse liver. Mol. Ther. 16, 931-941.
35. Mingozzi, F., and High, K. A. (2011a). Immune responses to AAV in clinical trials. Curr. Gene Ther. 11, 321-330.
36. Mingozzi, F., and High, K. A. (2011b). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12, 341-355.
37. Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C., and High, K. A. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13, 419-422.
38. Moore, M. W., Carbone, F. R., and Bevan, M. J. (1988). Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54, 777-785.
39. Nayak, S., and Herzog, R. W. (2011). Progress and prospects: immune responses to viral vectors. Gene Ther. 17, 295-304.
40. Nishimura, H., and Honjo, T. (2001). PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol. 22, 265-268.
41. Okazaki, T., Tanaka, Y., Nishio, R., Mitsuiye, T., Mizoguchi, A., Wang, J., Ishida, M., Hiai, H., Matsumori, A., Minato, N., and Honjo, T. (2003). Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat. Med. 9, 1477-1483.
42. Salomon, B., and Bluestone, J. A. (2001). Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19, 225-252.
43. Salvetti,A.,Oreve,S.,Chadeuf,G.,Favre, D., Cherel, Y., ChampionArnaud, P., David-Ameline, J., and Moullier, P. (1998). Factors influencing recombinant adeno-associated virus production. Hum. Gene Ther. 9, 695-706.
44. Sharpe, A. H., Wherry, E. J., Ahmed, R., and Freeman, G. J. (2007). The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8, 239-245.
45. Wallace, P. M., Rodgers, J. N., Leytze, G. M., Johnson, J. S., and Linsley, P. S. (1995). Induction and reversal of longlived specific unresponsiveness to a T-dependent antigen following CTLA4Ig treatment. J. Immunol. 154, 5885-5895.
46. Wang, L., Dobrzynski, E., Schlachterman, A., Cao, O., and Herzog, R. W. (2005). Systemic protein delivery by musclegene transfer is limited by a local immune response. Blood 105, 4226-4234.
47. Wang, L., Pino-Lagos, K., de Vries, V. C., Guleria, I., Sayegh, M. H., and Noelle, R. J. (2008). Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 105, 9331-9336.
48. Waterhouse,P.,Penninger,J. M.,Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., and Mak, T. W. (1995). Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988.
49. Xiao,X.,Li,J.,and Samulski,R. J. (1996). Efficient longterm gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70, 8098-8108.
50. Xin, K. Q., Mizukami, H., Urabe, M., Toda, Y., Shinoda, K., Yoshida, A., Oomura, K., Kojima, Y., Ichino, M., Klinman, D., Ozawa, K., and Okuda, K. (2006). Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells. J. Virol. 80, 11899-11910.
51. Zaiss, A. K., Liu, Q., Bowen, G. P., Wong, N. C., Bartlett, J. S., and Muruve, D. A. (2002). Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76, 4580-4590.
52. Zaiss, A. K., and Muruve, D. A. (2008). Immunity to adeno-associated virus vectors in animals and humans: a continued challenge. Gene Ther. 15, 808-816.
53. Zhang, Y., Chirmule, N., Gao, G., and Wilson, J. (2000). CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: role of immature dendritic cells. J. Virol. 74, 8003-8010.